NEWS
24 MAR 2009 Final Results Year Ending 31 DEC 2008 Financial Highlights include the following: Revenue increased to $6.1 million; Adjusted EBITDA $2.7 million; Maiden operating profit $1 million; Strong cash position of $4.3 million; No debt. 5 JAN 2009 Technology Transfer Agreement ABI sold the intellectual property pertaining to the Free Radical Enzymatic Device ("FRED") and future non-invasive exhaled breath test technology to Pulse Health, LLC , based in Portland, Oregon USA, for a cash sum of $3,000,000. ABI will further benefit from an exclusive manufacturing agreement to supply FRED Aldehyde Assay Tubes at a price fixed for three years and also earn a per tube royalty fee for every FRED Aldehyde Assay Tube sold over that period. For additional information, please call +1 856 848 2116 or 1.800.451.TEST. Government & Defense Procurement Information | 
